Multi-drug-resistant tuberculosis overview: Difference between revisions
No edit summary |
|||
| Line 64: | Line 64: | ||
====Special conditions==== | ====Special conditions==== | ||
| Line 85: | Line 76: | ||
===Future or investigational therapy=== | ===Future or investigational therapy=== | ||
==References== | ==References== | ||
Revision as of 12:51, 29 September 2014
|
Multi-drug-resistant tuberculosis Microchapters |
|
Differentiating Multi-drug-resistant tuberculosis from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Multi-drug-resistant tuberculosis overview On the Web |
|
American Roentgen Ray Society Images of Multi-drug-resistant tuberculosis overview |
|
Directions to Hospitals Treating Multi-drug-resistant tuberculosis |
|
Risk calculators and risk factors for Multi-drug-resistant tuberculosis overview |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Alejandro Lemor, M.D. [2]; João André Alves Silva, M.D. [3]; Ammu Susheela, M.D. [4]
Overview
Multi-drug resistant tuberculosis (MDR-TB) is defined as TB that is resistant at least to isoniazid (INH) and rifampicin (RMP). Isolates that are multiply-resistant to any other combination of anti-TB drugs but not to INH and RMP are not classed as MDR-TB.